The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes

Documenti analoghi

• Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability
  di: Gian Paolo Fadini, et al.
  Pubblicazione: (2026)
• Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
  di: João Sérgio Neves, et al.
  Pubblicazione: (2025)
• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  di: Nicklas S. Klepser, et al.
  Pubblicazione: (2025)
• Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
  di: Hannah Wallace, et al.
  Pubblicazione: (2025)
• Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
  di: Sama M. Abdel‐Rahman, et al.
  Pubblicazione: (2026)